Mesa Laboratories (MLAB) Stock Forecast, Price Target & Predictions
MLAB Stock Forecast
Mesa Laboratories stock forecast is as follows: an average price target of $120.00 (represents a -4.54% downside from MLAB’s last price of $125.71) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MLAB Price Target
The average price target for Mesa Laboratories (MLAB) is $120.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $120.00 to $120.00. This represents a potential -4.54% downside from MLAB's last price of $125.71.
MLAB Analyst Ratings
According to 2 Wall Street analysts, Mesa Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for MLAB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Mesa Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $120.00 | $140.86 | -14.81% | -4.54% |
| Jun 07, 2024 | Vijay Kumar | Evercore ISI | $120.00 | $104.80 | 14.50% | -4.54% |
The latest Mesa Laboratories stock forecast, released on Aug 27, 2024 by Brandon Couillard from Wells Fargo, set a price target of $120.00, which represents a -14.81% decrease from the stock price at the time of the forecast ($140.86), and a -4.54% decrease from MLAB last price ($125.71).
Mesa Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $120.00 | $120.00 | $120.00 |
| Last Closing Price | $125.71 | $125.71 | $125.71 |
| Upside/Downside | -4.54% | -4.54% | -4.54% |
In the current month, the average price target of Mesa Laboratories stock is $120.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -4.54% decrease as opposed to Mesa Laboratories's last price of $125.71. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Wells Fargo | - | Underweight | Initialise |
| Aug 06, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Jun 07, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Jan 04, 2024 | Evercore ISI | - | Outperform | Upgrade |
Mesa Laboratories's last stock rating was published by Wells Fargo on Aug 27, 2024. The company Initialise its MLAB rating from "null" to "Underweight".
Mesa Laboratories Financial Forecast
Mesa Laboratories Revenue Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $53.47M | $53.16M | $50.65M | $55.59M | $54.29M | $58.75M | - | $58.88M | $54.70M | $35.84M | $34.92M | $37.96M | $34.17M | $31.86M | $29.94M | $34.21M | $31.66M | $25.54M | $26.29M | $26.45M | $26.68M |
| Avg Forecast | $63.75M | $61.25M | $60.60M | $60.90M | $61.03M | $58.50M | $57.50M | $55.73M | $55.27M | $54.90M | $55.43M | $51.57M | $58.07M | $57.04M | $53.24M | $52.17M | $56.39M | $48.13M | $35.23M | $34.07M | $35.31M | $32.75M | $30.28M | $32.34M | $34.60M | $31.34M | $26.02M | $25.46M | $28.65M | $101.65M |
| High Forecast | $64.81M | $62.27M | $61.61M | $61.91M | $62.05M | $59.47M | $58.46M | $56.66M | $56.19M | $55.00M | $58.93M | $52.43M | $59.04M | $57.99M | $54.13M | $52.17M | $56.39M | $48.13M | $35.23M | $34.07M | $35.31M | $32.75M | $30.28M | $32.34M | $34.60M | $31.34M | $26.02M | $25.46M | $28.65M | $121.97M |
| Low Forecast | $62.69M | $60.23M | $59.59M | $59.89M | $60.02M | $57.53M | $56.54M | $54.81M | $54.35M | $54.80M | $51.93M | $50.71M | $57.10M | $56.09M | $52.35M | $52.17M | $56.39M | $48.13M | $35.23M | $34.07M | $35.31M | $32.75M | $30.28M | $32.34M | $34.60M | $31.34M | $26.02M | $25.46M | $28.65M | $81.32M |
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.97% | 0.96% | 0.98% | 0.96% | 0.95% | 1.10% | - | 1.04% | 1.14% | 1.02% | 1.03% | 1.08% | 1.04% | 1.05% | 0.93% | 0.99% | 1.01% | 0.98% | 1.03% | 0.92% | 0.26% |
Mesa Laboratories's average Quarter revenue forecast for Mar 24 based on 1 analysts is $55.27M, with a low forecast of $54.35M, and a high forecast of $56.19M. MLAB's average Quarter revenue forecast represents a 3.35% increase compared to the company's last Quarter revenue of $53.47M (Dec 23).
Mesa Laboratories EBITDA Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | $12.85M | $-60.00K | $-664.00K | $517.00K | $11.66M | $12.65M | - | $-110.00K | $5.51M | $9.63M | $6.86M | $11.84M | $823.00K | $8.74M | $6.21M | $7.08M | $-217.00K | $5.93M | $7.54M | $4.24M | $3.22M |
| Avg Forecast | $4.63M | $4.45M | $4.40M | $4.42M | $4.43M | $4.25M | $4.17M | $4.05M | $22.40M | $3.99M | $4.02M | $3.74M | $23.96M | $4.14M | $9.26M | $3.75M | $25.63M | $3.32M | $7.32M | $6.64M | $3.84M | $3.48M | $3.30M | $9.56M | $3.77M | $-597.62K | $6.66M | $5.06M | $3.12M | $5.04M |
| High Forecast | $4.70M | $4.52M | $4.47M | $4.49M | $4.50M | $4.32M | $4.24M | $4.11M | $26.89M | $3.99M | $4.28M | $3.81M | $28.75M | $4.21M | $11.12M | $3.75M | $30.75M | $3.99M | $8.79M | $7.97M | $3.84M | $4.17M | $3.30M | $11.47M | $3.77M | $-478.09K | $7.99M | $6.07M | $3.12M | $6.04M |
| Low Forecast | $4.55M | $4.37M | $4.33M | $4.35M | $4.36M | $4.18M | $4.10M | $3.98M | $17.92M | $3.98M | $3.77M | $3.68M | $19.17M | $4.07M | $7.41M | $3.75M | $20.50M | $2.66M | $5.86M | $5.31M | $3.84M | $2.78M | $3.30M | $7.65M | $3.77M | $-717.14K | $5.33M | $4.05M | $3.12M | $4.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.22% | -0.01% | -0.18% | 0.02% | 2.82% | 1.37% | - | -0.00% | 1.66% | 1.32% | 1.03% | 3.08% | 0.24% | 2.65% | 0.65% | 1.88% | 0.36% | 0.89% | 1.49% | 1.36% | 0.64% |
1 analysts predict MLAB's average Quarter EBITDA for Mar 24 to be $22.40M, with a high of $26.89M and a low of $17.92M. This is 74.34% upper than Mesa Laboratories's previous annual EBITDA (Dec 23) of $12.85M.
Mesa Laboratories Net Income Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | $2.12M | $-1.23M | $-937.00K | $611.00K | $451.00K | $1.31M | - | $-1.78M | $-2.06M | $3.72M | $2.00M | $3.92M | $-4.54M | $2.68M | $1.02M | $-1.68M | $-4.63M | $3.06M | $4.60M | $1.40M | $858.00K |
| Avg Forecast | $7.92M | $7.92M | $8.84M | $9.06M | $11.91M | $10.85M | $10.23M | $9.60M | $-3.80M | $9.69M | $9.69M | $4.66M | $-4.07M | $8.60M | $3.58M | $7.96M | $-4.35M | $-1.24M | $2.83M | $1.93M | $4.92M | $-19.20M | $15.67M | $1.58M | $4.48M | $-12.75M | $3.44M | $3.08M | $7.45M | $1.34M |
| High Forecast | $8.09M | $8.09M | $9.03M | $9.25M | $12.17M | $11.08M | $10.45M | $9.81M | $-3.04M | $10.12M | $26.49M | $4.77M | $-3.25M | $8.78M | $4.29M | $7.96M | $-3.48M | $-992.72K | $3.39M | $2.32M | $4.92M | $-15.36M | $18.81M | $1.89M | $4.48M | $-10.20M | $4.13M | $3.70M | $7.45M | $1.61M |
| Low Forecast | $7.75M | $7.75M | $8.65M | $8.86M | $11.66M | $10.61M | $10.01M | $9.39M | $-4.56M | $9.26M | $-6.46M | $4.56M | $-4.88M | $8.41M | $2.86M | $7.96M | $-5.22M | $-1.49M | $2.26M | $1.54M | $4.92M | $-23.04M | $12.54M | $1.26M | $4.48M | $-15.30M | $2.75M | $2.47M | $7.45M | $1.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -0.13% | -0.20% | -0.15% | 0.05% | 0.37% | - | 0.41% | 1.66% | 1.32% | 1.03% | 0.80% | 0.24% | 0.17% | 0.65% | -0.38% | 0.36% | 0.89% | 1.49% | 0.19% | 0.64% |
Mesa Laboratories's average Quarter net income forecast for Mar 24 is $-3.80M, with a range of $-4.56M to $-3.04M. MLAB's average Quarter net income forecast represents a -279.66% decrease compared to the company's last Quarter net income of $2.12M (Dec 23).
Mesa Laboratories SG&A Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | $29.18M | $27.18M | $27.04M | $27.68M | $24.57M | $27.40M | - | $30.04M | $25.98M | $16.33M | $16.28M | $17.68M | $17.93M | $14.40M | $14.17M | $15.38M | $15.67M | $9.98M | $9.73M | $10.98M | $9.79M |
| Avg Forecast | $29.33M | $28.18M | $27.88M | $28.02M | $28.08M | $26.91M | $26.45M | $25.64M | $25.43M | $25.26M | $25.50M | $23.72M | $26.72M | $26.24M | $15.70M | $26.06M | $25.67M | $15.65M | $12.41M | $15.75M | $16.07M | $14.91M | $13.79M | $21.82M | $15.75M | $14.27M | $11.21M | $6.52M | $13.04M | $15.30M |
| High Forecast | $29.82M | $28.65M | $28.35M | $28.49M | $28.55M | $27.36M | $26.90M | $26.07M | $25.85M | $25.30M | $27.11M | $24.12M | $27.16M | $26.68M | $18.84M | $26.06M | $25.67M | $18.78M | $14.89M | $18.90M | $16.07M | $14.91M | $13.79M | $26.18M | $15.75M | $14.27M | $13.45M | $7.83M | $13.04M | $18.36M |
| Low Forecast | $28.84M | $27.71M | $27.42M | $27.55M | $27.61M | $26.47M | $26.01M | $25.22M | $25.00M | $25.21M | $23.89M | $23.33M | $26.27M | $25.81M | $12.56M | $26.06M | $25.67M | $12.52M | $9.93M | $12.60M | $16.07M | $14.91M | $13.79M | $17.46M | $15.75M | $14.27M | $8.97M | $5.22M | $13.04M | $12.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 1.07% | 1.14% | 1.04% | 0.94% | 1.75% | - | 1.17% | 1.66% | 1.32% | 1.03% | 1.10% | 1.20% | 1.04% | 0.65% | 0.98% | 1.10% | 0.89% | 1.49% | 0.84% | 0.64% |
Mesa Laboratories's average Quarter SG&A projection for Mar 24 is $25.43M, based on 1 Wall Street analysts, with a range of $25.00M to $25.85M. The forecast indicates a -12.85% fall compared to MLAB last annual SG&A of $29.18M (Dec 23).
Mesa Laboratories EPS Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | $0.39 | $-0.23 | $-0.17 | $0.11 | $0.08 | $0.25 | - | $-0.34 | $-0.39 | $0.71 | $0.39 | $0.76 | $-0.89 | $0.52 | $0.23 | $-0.38 | $-1.06 | $0.74 | $1.18 | $0.36 | $0.22 |
| Avg Forecast | $1.46 | $1.46 | $1.63 | $1.67 | $2.20 | $2.00 | $1.89 | $1.77 | $1.91 | $1.79 | $1.79 | $0.86 | $1.69 | $1.58 | $1.21 | $1.48 | $1.80 | $1.29 | $1.06 | $1.02 | $0.91 | $0.84 | $0.58 | $0.55 | $0.83 | $1.27 | $1.00 | $1.18 | $1.38 | $1.25 |
| High Forecast | $1.49 | $1.49 | $1.67 | $1.71 | $2.24 | $2.04 | $1.93 | $1.81 | $1.95 | $1.87 | $4.88 | $0.88 | $1.72 | $1.62 | $1.24 | $1.48 | $1.80 | $1.29 | $1.06 | $1.02 | $0.91 | $0.84 | $0.58 | $0.55 | $0.83 | $1.27 | $1.00 | $1.18 | $1.38 | $1.50 |
| Low Forecast | $1.43 | $1.43 | $1.59 | $1.63 | $2.15 | $1.96 | $1.85 | $1.73 | $1.87 | $1.71 | $-1.19 | $0.84 | $1.65 | $1.55 | $1.19 | $1.48 | $1.80 | $1.29 | $1.06 | $1.02 | $0.91 | $0.84 | $0.58 | $0.55 | $0.83 | $1.27 | $1.00 | $1.18 | $1.38 | $1.00 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -0.13% | -0.20% | 0.07% | 0.05% | 0.21% | - | -0.19% | -0.30% | 0.67% | 0.38% | 0.83% | -1.06% | 0.90% | 0.42% | -0.46% | -0.83% | 0.74% | 1.00% | 0.26% | 0.18% |
According to 1 Wall Street analysts, Mesa Laboratories's projected average Quarter EPS for Mar 24 is $1.91, with a low estimate of $1.87 and a high estimate of $1.95. This represents a 388.89% increase compared to MLAB previous annual EPS of $0.39 (Dec 23).
Mesa Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ST | Sensata Technologies | $34.66 | $52.36 | 51.07% | Buy |
| FTV | Fortive | $73.60 | $86.38 | 17.36% | Buy |
| NOVT | Novanta | $171.12 | $175.00 | 2.27% | Buy |
| ESE | ESCO | $119.81 | $120.00 | 0.16% | Buy |
| VNT | Vontier | $33.14 | $32.67 | -1.42% | Buy |
| MLAB | Mesa Laboratories | $125.71 | $120.00 | -4.54% | Buy |
| BMI | Badger Meter | $209.08 | $199.20 | -4.73% | Hold |
| COHR | Coherent | $77.98 | $73.73 | -5.45% | Buy |
| ITRI | Itron | $102.54 | $89.91 | -12.32% | Buy |
MLAB Forecast FAQ
Is Mesa Laboratories a good buy?
Yes, according to 2 Wall Street analysts, Mesa Laboratories (MLAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of MLAB's total ratings.
What is MLAB's price target?
Mesa Laboratories (MLAB) average price target is $120 with a range of $120 to $120, implying a -4.54% from its last price of $125.71. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Mesa Laboratories stock go up soon?
According to Wall Street analysts' prediction for MLAB stock, the company can go down by -4.54% (from the last price of $125.71 to the average price target of $120), down by -4.54% based on the highest stock price target, and down by -4.54% based on the lowest stock price target.
Can Mesa Laboratories stock reach $200?
MLAB's average twelve months analyst stock price target of $120 does not support the claim that Mesa Laboratories can reach $200 in the near future.
What is Mesa Laboratories's current price target trend?
1 Wall Street analyst forecast a $120 price target for Mesa Laboratories (MLAB) this month, down -4.54% from its last price of $125.71. Compared to the last 3 and 12 months, the average price target decreased by -4.54% and decreased by -4.54%, respectively.
What are Mesa Laboratories's analysts' financial forecasts?
Mesa Laboratories's analysts financial forecasts for the fiscal year (Mar 2025) are as follows: average revenue is $232.77M (high $236.64M, low $228.89M), average EBITDA is $16.9M (high $17.18M, low $16.62M), average net income is $42.6M (high $43.52M, low $41.67M), average SG&A $107.09M (high $108.88M, low $105.31M), and average EPS is $7.85 (high $8.02, low $7.68). MLAB's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $246.5M (high $250.6M, low $242.4M), average EBITDA is $17.89M (high $18.19M, low $17.6M), average net income is $33.74M (high $34.47M, low $33.01M), average SG&A $113.41M (high $115.3M, low $111.52M), and average EPS is $6.22 (high $6.35, low $6.09).
Did the MLAB's actual financial results beat the analysts' financial forecasts?
Based on Mesa Laboratories's last annual report (Mar 2023), the company's revenue was $219.08M, which missed the average analysts forecast of $220.53M by -0.66%. Apple's EBITDA was $3.32M, missing the average prediction of $41.11M by -91.92%. The company's net income was $930K, missing the average estimation of $16.06M by -94.21%. Apple's SG&A was $109.88M, beating the average forecast of $94.72M by 16.01%. Lastly, the company's EPS was $0.17, missing the average prediction of $5.96 by -97.15%. In terms of the last quarterly report (Dec 2023), Mesa Laboratories's revenue was $53.47M, missing the average analysts' forecast of $54.9M by -2.60%. The company's EBITDA was $12.85M, beating the average prediction of $3.99M by 222.47%. Mesa Laboratories's net income was $2.12M, missing the average estimation of $9.69M by -78.17%. The company's SG&A was $29.18M, beating the average forecast of $25.26M by 15.51%. Lastly, the company's EPS was $0.39, missing the average prediction of $1.79 by -78.17%